Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma

Glioblastoma Multiforme Clinical Trial

Official title:

Fluorescein vs. Intraoperative MRI in the Resection of Malignant High Grade Glioma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02540135
• Other study ID #: 15-1313
• Status: Withdrawn
• Phase: N/A
• Start date: March 1, 2015
• Est. completion date: July 18, 2018

Study information

• Verified date: July 2018
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study plans to learn more about if fluorescein with intraoperative Magnetic Resonance Imaging (MRI) is as good as intraoperative MRI (iMRI) alone in detecting the presence of tumor tissue during surgery.

Both fluorescein and intraoperative MRI have been studied and routinely used to aid the neurosurgeon in distinguishing normal brain from tumor, helping the neurosurgeon to safely resect more tumor tissue during surgery.

This study will enroll patients with malignant high grade glioma who are going to have a surgery to remove their brain tumor.

For half of the patients, fluorescein and intraoperative MRI will be used together during surgery. For half of the patients, only intraoperative MRI will be used during surgery. iMRI is used as final verification of complete, safe resection in both arms.

Description:

Extent of surgical resection of malignant high grade glioma has been established as one of the most important predictors of overall survival and six-month progression free survival. Unfortunately, it is often difficult in surgery to distinguish between tumor and normal brain. Various technologies have been developed to help the surgeon more readily safely increase extent of resection in order to achieve an improved survival after glioblastoma resection. Fluorescein has been used at some institutions for a number of years to improve visualization of high-grade gliomas enabling their better resection. Intraoperative MRI has also been developed with similar intent, allowing the patient to be imaged intraoperatively to determine extent of resection and any need for further resection prior to leaving the operating room. While there is some evidence these technologies improve extent of resection in comparison to historical controls, they have never been tested against each other in any prospective fashion.

Intraoperative MRI has significant cost and significantly increases operative time. Fluorescein is a very inexpensive injectable agent and, if as good at achieving gross total resection as intraoperative MRI, would offer patients similar surgical outcomes with less anesthetic time and cost than intraoperative MRI. This study aims to investigate the value of fluorescein or intraoperative MRI in malignant glioma patients' extent of tumor resection in a prospectively randomized manner.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 18, 2018
• Est. primary completion date: July 18, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Presents with presumed or pathologically proven enhancing primary or secondary high grade glioma for surgical resection

• Eligible for gross total resection of enhancing component of tumor

• Karnofsy performance status >/= 70%

Exclusion Criteria:

• Presence of multi-focal disease

• Disease that crosses the mid-line

• History of adverse reaction to flourescein

• Known ongoing pregnancy

• Inability to grant consent

• Contraindication to perform iMRI

• Contraindication to flourescein

Related Conditions & MeSH terms

• Anaplastic Astrocytoma
• Astrocytoma
• Glioblastoma
• Glioblastoma Multiforme
• Glioma
• High Grade Malignant Neoplasm
• Neoplasms

Intervention

Other:
• fluorescein
fluorescein and conventional neuro-navigation
• intraoperative MRI
conventional neuro-navigation and iMRI

Locations

Country	Name	City	State
United States	University of Colorado Anschutz Medical Campus	Aurora	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Extent of resection	This outcome will utilize tumor volumetry of residual enhancing tumor after resection.	36 hours
Secondary	Surgical time difference	This outcome will evaluate the difference in length of surgery time between each arm.	36 hours